Guidance, NICE advice and quality standards in development | Guidance

Showing 41 to 50 of 344

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]	Technology appraisal guidance	13 January 2027
Benralizumab for previously treated severe nasal polyps [ID1659]	Technology appraisal guidance	TBC
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]	Technology appraisal guidance	TBC
Bepirovirsen for treating chronic hepatitis B [ID6608]	Technology appraisal guidance	TBC
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]	Technology appraisal guidance	15 July 2026
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537	Technology appraisal guidance	26 August 2026
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]	Technology appraisal guidance	20 February 2019
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]	Technology appraisal guidance	TBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]	Technology appraisal guidance	TBC
Botulinum toxin type A for preventing episodic migraine [ID6450]	Technology appraisal guidance	TBC